A peer-reviewed article in JACC: Advances has demonstrated that a risk prediction algorithm incorporating the credit card-sized HeartBeam ECG device can accurately identify heart attack risk in patients presenting with chest pain, according to HeartBeam Inc. (NASDAQ: BEAT). The proof-of-concept study evaluated 184 patients and found that the algorithm achieved an “area under the curve” (“AUC”) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms, rising to 92.9% when a personal, symptom-free baseline ECG was available for comparison.
HeartBeam said the results support heart attack detection as a future indication for the HeartBeam System and advance its broader clinical program. The company is a medical technology company focused on transforming cardiac care by providing powerful cardiac insights. Its platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence, allowing physicians to identify cardiac health trends and acute conditions and direct patients to the appropriate care outside of a medical facility.
HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. The HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to technology enablement.
The implications of this study are significant for the healthcare industry and patients. Chest pain is a common symptom in emergency departments, and rapid, accurate identification of heart attacks is critical. The ability to use a portable, credit card-sized device to assess risk could streamline triage, reduce unnecessary hospital admissions, and expedite care for those in need. For patients, this technology could mean faster diagnosis and treatment, potentially improving outcomes. For healthcare systems, it could reduce costs by minimizing unnecessary testing and hospital stays.
For more details, the full press release is available at https://ibn.fm/ainxV. Additional information about HeartBeam and its cleared indications for use can be found at https://www.heartbeam.com/indications.
